Comparison of Partial Stomach-Partitioning and Conventional Gastrojejunostomy for the Treatment of Gastric Outlet Obstruction in Advanced Gastric Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The primary goal of clinical treatment is to relieve obstruction, restore oral feeding, improve nutritional status and improve quality of life in patients with advanced gastric cancer outflow tract obstruction. At present, the common surgical treatment for relieving obstruction is traditional gastrojejunostomy. Although the operation can relieve the obstruction, there are problems such as tumor-induced bleeding, anastomotic invasion, and high incidence of delayed gastric emptying after operation. Partitioned gastrojejunostomy effectively relieves obstruction by anastomosis of a part of the stomach to the jejunum, and isolates the tumor from the anastomosis, which is beneficial to food emptying and can reduce the risk of bleeding and anastomotic invasion. The safety and efficacy of these two procedures are still controversial, mainly because previous studies were retrospective studies or included a small sample size or enrolled patients with different pathological characteristics. The purpose of this study was to compare the safety and efficacy of separated and traditional gastrojejunostomy in the treatment of advanced gastric cancer outflow tract obstruction, and to provide the best choice for the treatment of advanced gastric cancer outflow tract obstruction.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18-75 lat
- •Zaawansowany rak dolnej części żołądka, który nie może być całkowicie usunięty
- •Potwierdzony stan zaparcia żołądka (niemożność przełykania pokarmów)
- •Ogólny stan zdrowia oceniony na 0-2 punkty (może być leczony operacyjnie)
- •Prawidłowe funkcje wątroby, nerek i serca (w normie laboratoryjnej)
- •Brak wcześniejszego chemioterapii, radioterapii lub innych leczenia przeciwnowotworowego
- •Żenczyny w wieku rozrodczym muszą stosować antykoncepcję
- •Świadoma zgoda pacjenta i jego rodziny na uczestnictwo w badaniu
✗ Disqualifies
- •Inny nowotwór złośliwy w ciągu ostatnich 5 lat
- •Aktywna choroba autoimmunologiczna (w ciągu ostatnich 4 tygodni)
- •Wcześniejszy przeszczep szpiku kostnego lub narządu
- •Poważne choroby serca uniemożliwiające operację
- •Niemożność uczestniczenia w programie badania lub wypełniania jego wymagań
- •Ciąża lub karmienie piersią
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- July 8, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Guangxi Medical University Cancer Hospital
Nanning, China
Trial contact
Yuzhou Qin
Liucheng Wu
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.